Application of fungus polysaccharide sulfate in the preparation of chronic nephritis and kidney failure treating medicine

A fungal polysaccharide, chronic nephritis technology, applied in the direction of drug combination, pharmaceutical formula, organic active ingredients, etc., can solve the problems of reducing urinary albumin, not finding the research report of Poria polysaccharide sulfate in the treatment of kidney disease, etc.

Inactive Publication Date: 2004-12-29
NANJING UNIV
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example: Akima K et al. (1996, 1999) used acidic mucopolysaccharide (preferably sulfated hyaluronic acid semi-synthetic product) and dextran sulfate with anticoagulant activity to treat interstitial nephritis and glomerulonephritis and lupus nephritis (Akima K etc., Japanese patent: 08-301771; U.S. patent: 5981509); Egidio M et al (1994) treated diabetic nephropathy with polysaccharide sulfate ester derived from mucopolysaccharides, and the effect of reducing urinary albumin was particularly good (Egidio M et al , Japanese Patent: 06-091713); Xu Zuhong et al. (1995, 1998) disclosed a new preparation method of fucoidan sulfate and its application as a drug for the treatment of renal failure (Chinese Patent: 95112292.4, 98120283.7); Bi Aifang ( 1998) applied for a patent on the use of fucoidan sulfate as a drug for the treatment of glomerular diseases (Chinese patent: 98110201.8), but none of the above patents for the treatment of chronic nephritis and renal failure involved β-glucan sulfate derived from fungi
[0007] So far, the vast majority of studies on the pharmacological effects of pachymansin have focused on immune regulation and anti-tumor activity, and no research reports on the treatment of kidney diseases by pachymansan sulfate have been found.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Embodiment 1: fungal (poria cocos, polyporus cocos, schizophyllum etc.) polysaccharide sulfate acute toxicity test

[0018] 1. Experimental animals Kunming white mice, weighing 20±2g.

[0019] 2. Experimental sample preparation Take 6g of the sample and completely dissolve it in 40ml of normal saline to make a solution with a concentration of 150mg / ml for use.

[0020] 3. Toxicity test Take 20 mice, half male and half male, each mouse is given sample solution 0.04ml / g according to body weight, orally administered, which is equivalent to 6000mg / kg, and observed for 10 days. All the animals survived in healthy condition, and no abnormalities were found in the organs such as liver and kidney after dissection. The maximum tolerated dose of this product to mice orally is above 6000mg / kg, according to the United States on LD 50′ The toxicity classification of the value belongs to the low toxicity category (greater than 5000mg / kg).

Embodiment 2

[0021] Embodiment 2: the drug efficacy experiment of fungal (poria cocos, polyporus, schizophyllum, etc.) polysaccharide sulfate in the treatment of chronic renal failure

[0022] 1. After adapting to adenine chronic renal failure (CRF) animal model SD male rats for 1 week, they were randomly divided into 5 groups according to body weight, with 14 rats in each group, given adenine 250 mg / kg body weight every day, administered by intragastric administration, 1 day per day times, for 21 consecutive days. Adenine was made into a suspension of 25 mg / ml, and the volume of gavage was 10 ml / kg rat weight. Another 10 rats served as the normal control group and were not given adenine.

[0023] 2. Animals were divided into normal control group, given the same amount of distilled water; model control group, given the same amount of distilled water; dexamethasone group, dexamethasone 0.1mg / kg; fungal polysaccharide sulfate group, fungal polysaccharide sulfate 0.45g / kg kg. All groups we...

Embodiment 3

[0070] Jiang ××, male, 46 years old, a cadre. Long-term high blood pressure, and later induced uremia due to lung infection. Serum creatinine was 1600, blood urea nitrogen was 28, and then renal dialysis was performed 2-3 times a week. Half a year after dialysis, he took pachyphyllan sulfate, started to take 6 tablets a day, each tablet contained 500mg, a total of 3000mg was taken in 2 times for 3 months, and then reduced to 2000mg per day, and continued to take the medicine. It reflects that after taking the medicine, the effect is rapid and the curative effect is obvious, the physical fitness is enhanced, the appetite is increased, the whole body itching disappears, the spirit improves, the urine protein, blood creatinine and blood urea nitrogen drop quickly, and there is no rebound. Now the ammonia odor in the mouth has completely disappeared, and the urine output has increased significantly. Hemodialysis is performed once a week, and the blood creatinine has dropped to 80...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is new use of mycose sulfate in pharmaceutical field. The medicine has obvious effects of obviously lowering kidney coefficient, serum inosine and urea nitrogen level, obviously increasing total serum protein and albumin, increasing urine creatinine exhaust amount, obviously decreasing exhausted urine protein, etc. It is used in treating nephritis and kidney failure disease and has the advantages of obvious curative effect, less toxic side effect, etc.

Description

1. Technical field [0001] The invention relates to a new application of a microbial extract, in particular to a new application of a fungal polysaccharide sulfate in the preparation of medicines for treating chronic nephritis and renal failure. 2. Background technology [0002] The kidney is an important urinary organ. The incidence of chronic renal insufficiency is increasing year by year. In addition to the significantly increased incidence of diabetic nephropathy and hypertensive kidney damage, some new glomerular diseases have also been recognized, such as lipoprotein nephropathy, Obesity-related nephropathy, etc. The final common outcome of chronic renal insufficiency is chronic renal failure (chronic renal failure.CRF), such as chronic glomerulonephritis, as the disease progresses, more patients will develop renal failure after 3-20 years. Renal failure is a syndrome of water and electrolyte disorders, acid-base balance disorders, and multiple organ dysfunctions cause...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/737A61P13/12
Inventor 焦庆才刘茜陈群李绪亮
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap